COSCIENS Biopharma Inc (CSCID)

COSCIENS Biopharma Inc. is a Toronto-based life science company incorporated in 1990 and listed on OTC Markets as common stock. The company develops and commercializes products for cosmeceutical, nutraceutical, and pharmaceutical applications in the United States, Germany, the United Kingdom, and other international markets. Its operations are organized into Active Ingredient and Pharmaceutical segments. The active ingredient portfolio includes oat beta glucan, oat powder and peptides, oat oil, and avenanthramides, which are used in health, wellness, and inflammation-related applications across cosmeceutical and pharmaceutical settings. The pharmaceutical business includes Macrilen/Ghryvelin (macimorelin), an oral compound that stimulates growth hormone secretion from the pituitary gland. COSCIENS Biopharma sells through a distribution network and has license agreements with Pharmanovia, Davimed GmbH, NK MEDITECH Ltd, Agriculture Canada, the Canadian Government, and the University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and adopted its current name in August 2024.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-CSCI.D
$7.77
51.2% Upside
Bargain
Not available
Not available
Fair
0.0%
0.4x
0.7x
5.376 M
2.407 M
27.3%
99.4%
5.8
112.7%
Valuation • Fair Value

COSCIENS Biopharma Inc (OTC-CSCI.D) Fair Value by Valuation Model

Review the available estimates for COSCIENS Biopharma Inc (OTC-CSCI.D), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$7.77

Estimated upside of 51.2% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$8.08

Discounted cash flow valuation reference.

Comps Fair Value

$7.71

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 4 available valuation references for COSCIENS Biopharma Inc (OTC-CSCI.D) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for COSCIENS Biopharma Inc (OTC-CSCI.D)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

7.999 M

Current operating scale indicator.

Revenue Forecast

29.144 M

Forward revenue estimate.

EBITDA

-7.57 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review COSCIENS Biopharma Inc (OTC-CSCI.D) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for COSCIENS Biopharma Inc (OTC-CSCI.D)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-1.22

Higher caution zone on this screen.

Altman Z-Score

5.8

Relatively strong balance-sheet zone.

FCF / Net Income

112.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for COSCIENS Biopharma Inc (OTC-CSCI.D). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for COSCIENS Biopharma Inc (OTC-CSCI.D)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for COSCIENS Biopharma Inc (OTC-CSCI.D). No upcoming dividend amount or event date is currently available.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for COSCIENS Biopharma Inc (OTC-CSCI.D) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for COSCIENS Biopharma Inc (OTC-CSCI.D) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for COSCIENS Biopharma Inc (OTC-CSCI.D) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for COSCIENS Biopharma Inc (OTC-CSCI.D) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for COSCIENS Biopharma Inc (OTC-CSCI.D) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ Fast Investor Answers

COSCIENS Biopharma Inc (OTC-CSCI.D) Stock FAQ

Data-supported answers about COSCIENS Biopharma Inc (OTC-CSCI.D), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$7.77
Estimated upside 51.2%
Valuation Rating
Undervalued
Estimated upside of 51.2%
Financial Health
Fair
Current financial-health read

The current fair value estimate for COSCIENS Biopharma Inc (OTC-CSCI.D) is $7.77. This implies an estimated upside of 51.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 51.2% versus the current market price.

The current financial health read for COSCIENS Biopharma Inc (OTC-CSCI.D) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for COSCIENS Biopharma Inc (OTC-CSCI.D).

The current market capitalization listed for COSCIENS Biopharma Inc is 5.376 M.

The current enterprise value listed for COSCIENS Biopharma Inc is 2.407 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for COSCIENS Biopharma Inc is OTC-CSCI.D, and the stock is listed on OTC Markets.

COSCIENS Biopharma Inc (OTC-CSCI.D) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for COSCIENS Biopharma Inc is 27.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for COSCIENS Biopharma Inc is 99.4%. Free float helps investors understand how much of the share base is available for public trading.